SCYNEXIS Stock
SCYNEXIS, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Country
- United States
- CEO
- David Angulo
- Employees
- 18
- Market cap
- $23 M
- IPO
- 02/05/2014
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was…
SCYNEXIS stock: price history
1D
-6.1%
1W
-10.0%
1M
-10.7%
6M
-58.7%
YTD
-27.5%
1Y
-42.7%
2Y
-70.2%
5Y
-91.8%
10Y
-98.8%
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~53% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 12/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about SCYNEXIS
Analyst assessment of SCYNEXIS
0
STRONG BUY
13
BUY
1
HOLD
0
SELL
0
STRONG SELL
14
TOTAL · Buy
As of: 13/08/2026
SCYNEXIS stock metrics
P/E
-1.99
P/B
0.65
EV/EBITDA
-1.42
RETURN ON EQUITY
11.1%
NET MARGIN
3,147.7%
DEBT/EQUITY
0.03
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
96.5%
FLOAT SHARES
6,070,077
AVG. DAILY VOLUME (30D)
393,500
Insider transactions (SEC)
Burke Steven Keith
ANIDO ARMANDO
HASTINGS DAVID C
HANHAM ANN
Macdonald Guy
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about SCYNEXIS stock
What does SCYNEXIS do?
SCYNEXIS, Inc. is a company in the Healthcare sector, Medical - Pharmaceuticals industry, headquartered in United States.
The CEO is David Angulo, the company employs around 18 people.
The IPO was on 02/05/2014; the stock trades on NASDAQ under the ticker SCYX.
What do analysts say about SCYNEXIS stock?
14 analysts rate the stock, the consensus is Buy (as of 13/08/2026).
This is an external assessment, not a statement by Market Jury.
When does SCYNEXIS report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 53% stronger than usual.
Does SCYNEXIS pay a dividend?
No, SCYNEXIS currently does not pay a dividend.
Which stocks are comparable to SCYNEXIS?
Comparable stocks include Corcept Therapeutics, Liquidia, Latigo Biotherapeutics, Helus Pharma, Eli Lilly and Company, Johnson & Johnson, AbbVie and Merck &.
How can I get SCYNEXIS stock analyzed?
Clicking "Analyze stock" lets five strategies assess SCYNEXIS against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.